Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.
Abstract: Artificial elimination of rtA181S from the rtA181S + T184I + M204I mutant restored viral susceptibility to ADV but decreased viral replication capacity.
Abstract: Compared with wild-type, the rtA181S + T184I + M204I mutant had 53.7% lower replication capacity and >1000-, 3.9-, and 383.3-fold greater LAM, ADV, and ETV resistance, respectively, but remained sensitive to tenofovir.
Abstract: Longitudinal analysis of the clinical course of resistant mutant evolution for four representative cases showed that rtA181S + T184I
Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Introduction: These two categories are known as classical mutations, which include: (i) M204I/V mutation, which associates with LAM or LDT resistance; (ii) N236T or A181T/V mutations, which associate with ADV resistance; (iii) M204V + L180M and either T184A/G/I/L/S or S202G or M250V to develop resistance to ETV.
Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
PMID: 31189581
2019
Journal of clinical microbiology
Result: In addition, except for only 1 patient with a mutation at rt181 (A181T) in the ALD group, there was not any primary resistance mutation (i.e., I169T, T184A/C/F/G/I/L/M/S, A194T, S202C/G/I, M204I/V/S, N236T, or M250I/L/V) and secondary resistance mutation (i.e., V173L or L180M) found in treatment-naive patients, while 9 putative resistance mutations and 51 pretreatment mutations were detected in these patients.
Discussion: Currently, the well-known classical NA resistance mutat
Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018.
Introduction: A total of 8 HBV classical mutation sites are conventionally tested for HBV patients in most clinical labs, including M204I/V, L180M, T184A/F/I/L/S, L181T/V, M250I/L/V, M236T, S202G, and V207I.
Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
Result: ETVr substitutions at rtT184 (rtT184C/G/I/S) have been shown to exhibit low-level ETVr and have only been observed in combination with other ETVr substitutions in patients with virologic breakthrough.( 12 ) The novel emergent rtV191I substitution was phenotyped in an ETVr HBV RT background of rtL180M, rtT184S, and rtM204V and displayed reduced ETV susceptibility (15-fold greater than WT; Table 2) within the range observed for LVDr HBV.
Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant.
Result: We also screened several mutations relevant to antiviral resistance, such as I169L, L180M, A181V, T184I, S202C, M204V/I, N236T and M250I in the RT region.
HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.
Introduction: According to several clinical practice guidelines and authoritative reviews, NUCr substitutions can be classified into two categories: primary NUCr substitutions at 8 codons (rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V, rtN236T and rtM250I/L/V) and secondary substitutions at 3 codons in RT<
HBV mutation literature information.
PMID: 
2022
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT